Physician profile
Lorne D Kapner
NPI 1144255621
$2,000.12
in general payments reported to CMS, 2019-2025
18 companies · $183 in 2025
The $183 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $263 · 2020: $157 · 2021: $562 · 2022: $329 · 2023: $370 · 2024: $137 · 2025: $183.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $672 · Entertainment: $17.64.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $672.29 |
| Entertainment | $17.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $531.83 | 2019-2025 | Clareon, Clareon Panoptix Pro |
| Johnson & Johnson Surgical Vision, INC. | $523.66 | 2019-2023 | Tecnis Iol |
| Glaukos Corporation | $148.65 | 2022-2024 | Idose |
| Aerie Pharmaceuticals, INC. | $127.98 | 2019-2021 | |
| Abbvie INC. | $105.13 | 2022-2025 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $86.68 | 2019-2021 | |
| Rxsight INC | $62.40 | 2021-2025 | Rxsight Injector Cartridge, Rxsight Contact Lens, Rxsight Injector Handpiece |
| Beaver-Visitec International, INC. | $59.31 | 2021-2023 | |
| Bausch & Lomb Americas INC. | $56.67 | 2024-2025 | Stellaris, Ic-8 Apthera Iol, Envista Mx60 Iol |
| Thea Pharma INC. | $56.35 | 2022-2025 | Iyuzeh |
| New World Medical,INC. | $55.70 | 2023 | |
| Oyster Point Pharma, INC. | $41.99 | 2022-2024 | Ryzumvi, Tyrvaya |
| Allergan, INC. | $34.05 | 2020-2021 | |
| Optos, INC. | $30.57 | 2020-2025 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
| Shire North American Group INC | $27.82 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $19.18 | 2021 | |
| Kala Pharmaceuticals, INC. | $17.89 | 2019 | |
| Ocular Therapeutix, INC. | $14.26 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lorne Kapner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.